Sep 30 2024 23 mins
Visit https://www.peervoice.com/SBN860 to view the entire programme with slides. After completing “Diana N. Ionescu, MD - Pathological Assessment of HER2 Status in Gastric and Gastroesophageal Cancers: Important Steps That Can Impact Outcomes”, participants will be able to: Describe the prognostic value of HER2 status in gastric/gastroesophageal junction (GEJ) cancers; Use the clinical data for HER2-directed therapies for gastric/GEJ cancers to evaluate the importance of establishing HER2 status; Discuss the key differences in HER2 expression of gastric/GEJ cancers and breast cancer; and Explain why retesting for HER2 status is recommended in patients who are progressing on a trastuzumab-based therapy.